EICHOR
● Not Yet Recruiting
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
Condition: Seborrheic Dermatitis · Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
About this study
This study will assess the safety and efficacy of Roflumilast foam 0.3% (ZORYVE®) versus vehicle applied once a day for 8 weeks by trial participants with seborrheic dermatitis.
This description comes directly from the study's public registry record.
Talk to the study team
Huadong Medicine · +86-0571-89918267 · cxyguweizhi@eastchinapharm.com
Always discuss trial participation with your own doctor first.
Locations (44)
| The First Affiliated Hospital of Wannan Medical Hospital | Wuhu, Anhui, China | — |
| The Second Affiliated Hospital of Wannan Medical Hospital | Wuhu, Anhui, China | — |
| The first affilated hospital of Fujian Medical university | Fuzhou, Fujian, China | — |
| The Second Affiliated Hospital of Xiamen Medical College | Xiamen, Fujian, China | — |
| Dermatology Hospital of Southern Medical University | Guangzhou, Guangdong, China | — |
| Shenzhen Children's Hospital | Shenzhen, Guangdong, China | — |
| Hainan Fifth People's Hospital | Haikou, Hainan, China | — |
| Beijing Children's Hospital, Capital Medical University Baoding Hospital | Baoding, Hebei, China | — |
| The Second Affiliated Hospital of Harbin Medical University | Harbin, Heilongjiang, China | — |
| The Second Affiliated Hospital of Henan University of science and technology | Luoyang, Henan, China | — |
| Nanyang Central Hospital | Nanyang, Henan, China | — |
| Sanmenxia Central Hospital | Sanmenxia, Henan, China | — |
+ 32 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07683806